Compare ARK Genomic Revolution ETF (ARKG) vs Axon Enterprise Inc (AXON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Axon Enterprise Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.55, while Axon Enterprise Inc trades at $545 (market cap $45.60B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Axon Enterprise Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | AXON | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $870.97 |
52-Week Low | $23.09 | $345.94 |
Market Cap | — | $45.60B |
Enterprise Value | — | $46.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Axon trades at $565.80, down 2.78% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings show mixed quarterly beats, with Q2 2026 results pending. The company maintains solid revenue growth, reaching $2.78 billion in 2025, though valuation ratios like P/E of 228.15 appear elevated. Positive news includes a Zacks Strong Buy upgrade and federal rulings favoring nonlethal enforcement technology.
Outlook remains positive with an 80.95% analyst buy rating and $640.33 consensus price target, suggesting 13% upside. Key risks include high valuation sensitivity and execution challenges in scaling software services. Investor sentiment is buoyed by institutional interest and strategic expansions in counter-drone capabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →
